



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_103_24

You asked:

1. For the 4 months from September to December 2023, how many patients received the following intra-vitreous treatments for any eye condition:

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab – Ongavia

We are unable to provide the number of patients who received the intra-vitreous treatment as we only monitor the number of injections/implants. The figures quoted below in response to this question relate to the number of injections/implants administered between September and December 2023.

Aflibercept	1829
Bevacizumab	15
Brolucizumab	0
Dexamethasone	14
Faricimab	729
Ranibizumab – Lucentis	9
Ranibizumab – Ongavia	0

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Our response below only includes new patients for the conditions DMO/RVO & CNV as this is what we monitor in Medicines Management. Additionally, we can

Cadeirydd/Chair: Jonathan Morgan **Prif Weithredwr/Chief Executive:** Paul Mears

*Croeso i chi ohebu â'r bwrdd iechyd neu ein ffonio yn y Gymraeg neu'r Saesneg. Byddwn yn ymateb yn yr un iaith a ni fydd hyn yn arwain at oedi.
You are welcome to correspond with the Health Board or phone us in Welsh or English. We will respond accordingly and this will not delay the response.*

<https://ctmuhb.nhs.wales>

only give numbers of new patients for the drugs we monitor i.e. Aflibercept, Faricimab & Ranibizumab (Lucentis).

Aflibercept	50
Bevacizumab	N/K
Brolucizumab	0
Dexamethasone	N/K
Faricimab	13
Ranibizumab – Lucentis	0
Ranibizumab – Ongavia	0